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Abstract 
BACKGROUND AND OBJECTIVES: A process for monitoring the prescribing of common pregnancy category D or X medications in 
women of childbearing age (ages 12 to 50) was developed and implemented by clinical pharmacists within a residency clinic. The 
project goals were to determine 1) if providers value the monitoring of their prescribing practices, 2) if they value the process used by 
the clinic, and 3) if providers report changing prescribing practices or note increased awareness when prescribing pregnancy category 
D or X medications in women of childbearing age as a result of the monitoring process. METHODS: An electronic survey was 
distributed to the 43 providers currently practicing in the clinic. Survey questions covered topics including value of monitoring 
prescribing practices for pregnancy category D or X medications in women of childbearing age, value of the specific monitoring 
process used at the clinic, frequency of consideration of pregnancy status and contraception use when prescribing medication, and 
suggestions for improvement on the monitoring process. RESULTS:  The response rate was 81.4% (n=35). Results showed all 
responders valued the monitoring of their prescribing of pregnancy category D or X medications and the monitoring process used by 
the clinic. Providers reported the monitoring process increased how often they thought about a patient’s pregnancy status and 
contraception use when prescribing medications. CONCLUSIONS: The monitoring process is valued by providers and impacts 
prescribing practices. It is a quality process that could be implemented by clinical pharmacists in other primacy care practices to 
enhance the safe prescribing of medications for women of childbearing age. 
 
 
Introduction 
In 2008, about half (51%) of pregnancies in the United States 
were unintended.1 Prescription medication use is common 
and increasing during pregnancy. In 2006-2008, 93.9% of 
women reported taking at least one medication during 
pregnancy.2 The average number of medications used at any 
time during pregnancy increased from 2.5 in 1976-1978 to 4.2 
in 2006-2008.2 Two of the top 10 drugs by monthly 
prescription in the United States are pregnancy category D or 
X.3 Pregnancy categories indicate the potential of drugs to 
cause birth defects if used during pregnancy, with D and X 
having positive evidence of human fetal risk.  
 
A process for monitoring the prescribing of common 
pregnancy category D or X medications in women of 
childbearing age (ages 12 to 50) was developed and has been  
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implemented by clinical pharmacists within a family medicine 
residency clinic since October 2011. The clinic serves a young, 
urban, underserved patient population, which includes a 
significant number of women of childbearing age. These 
women often have a higher incidence of chronic diseases at 
younger ages than expected with the general population4,5 
and have high numbers of unplanned pregnancies.1 The 
intent of the monitoring process was to identify women of 
childbearing age without documented contraception or 
sterilization who were prescribed pregnancy category D or X 
medications. The monitoring process was conducted about 
every six months. 
 
As a result of creating and implementing this monitoring 
process, it was necessary to determine providers’ perceptions 
of the monitoring process. The goals were to determine 1) if 
providers value the monitoring of their prescribing practices, 
2) if they value the process used by the clinic, and 3) if 
providers report changing prescribing practices or note 
increased awareness when prescribing pregnancy category D 
or X medications in women of childbearing age, as a result of 
the developed monitoring process. 
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Methods 
A survey was developed to determine providers’ perceptions 
of the monitoring process of prescribing practices for 
pregnancy category D or X medications in women of 
childbearing age. Demographic information was collected, 
including gender and provider type: first-year resident (G1), 
second-year resident (G2), third-year resident (G3), faculty 
physician, or nurse practitioner (NP). Not all providers may 
have had patients who qualified for monitoring (i.e. on a 
pregnancy category D or X medication without documented 
contraception, postmenopausal status, or sterilization). A 
screening question assessed whether or not the provider 
received a patient list of women of childbearing age taking 
pregnancy category D or X medications, either in January 
2012 or January 2013. For those who did not, a final question 
asked if they would value this type of monitoring and to 
explain why or why not. For those who did receive a patient 
list, questions on the value of this type of monitoring and the 
specific monitoring process used at the clinic were assessed 
on a 5-point Likert-type scale (strongly disagree to strongly 
agree). Using the same scale, these respondents were also 
asked to assess change in prescribing practices as a result of 
the monitoring process used at the clinic. These respondents 
were asked to assess the frequency of their consideration of 
pregnancy status and contraception use of a woman of 
childbearing age when prescribing medication using a 5-point 
Likert-type scale (never to always). Finally, respondents who 
did receive patient lists were asked three open-ended 
questions on how the monitoring process changed their 
prescribing practices, what is valued about the process, and 
suggestions for improvement on the monitoring process used 
by the clinic.  
 
The survey was distributed to the 43 providers currently 
practicing in the clinic using Research Electronic Data Capture 
(REDCap Software, Version 4.13.18). Providers were sent an 
e-mail announcement and link to the survey. Reminder e-
mails were sent to non-responders after one week and again 
five days later, with data collection concluding two weeks 
after initial distribution.   
 
The University of Minnesota Institutional Review Board 
Human Subjects Committee determined review was not 
required. 
 
Results 
The response rate to the survey was 81.4% (n=35). 
Demographics are shown in Table 1. Thirty-one (88.6%) 
respondents reported receiving a patient list. Of those 
respondents, all strongly agreed or agreed that the 
monitoring of their prescribing of pregnancy category D or X 
medications in women of childbearing age and the 
monitoring process used by the clinic was valuable (Table 2). 
The majority of providers reported agreement with 
statements that they plan to change (83.9%) or have changed 
(64.5%) how they approach prescribing pregnancy category D 
or X medications as a result of the clinic’s monitoring process 
(Table 2). Eight providers (26.7%) reported they frequently 
and zero always thought about a patient’s pregnancy status 
and contraception use before the monitoring process. Twenty 
(64.5%) reported they frequently and four (12.9%) always 
thought about it after the monitoring process was 
implemented (Table 3). Most of the responses to the open-
ended questions noted the monitoring increased awareness 
when prescribing pregnancy category D or X medications 
(Table 4). All respondents who did not receive a patient list 
reported they thought it would be valuable to have their 
prescribing of pregnancy category D or X medications in 
women of childbearing age monitored.  
 
Discussion 
The survey showed providers value the monitoring of their 
prescribing of pregnancy category D or X medications and the 
monitoring process used by the clinical pharmacists within 
the clinic. It also highlighted the impact of the monitoring 
process on providers; after implementation, 24 providers 
frequently or always considered pregnancy status before 
prescribing compared to 8 providers before the monitoring 
process. Based on the results of the provider survey, the clinic 
decided to continue the monitoring process. 
 
The monitoring process highlights an important role for 
clinical pharmacists to support patient safety and resident 
education through quality improvement processes. 
Pharmacists have been demonstrating their impact in these 
areas for many years.6-9 The monitoring process also led to 
additional provider education on the use of medications in 
women of childbearing age, particularly for those who have a 
greater likelihood of having an unplanned pregnancy. Clinical 
pharmacists provided extra didactic presentations within the 
pharmacotherapy curriculum for the family medicine 
residency program. 
 
Different providers in the clinic during the span of the 
monitoring process created a barrier to surveying the 
providers. The G3 resident class from the previous year was 
no longer at the clinic at the time the survey was distributed, 
but may have received patient lists in January 2012. One G2 
resident who received patient lists left the program before 
the survey was distributed. This represents potentially 
missing data from the 10 residents who graduated and the 
one resident who left. 
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This monitoring process highlights one model of ongoing 
surveillance and aids in active panel management. This type 
of monitoring process could also be applied to medication 
alerts and major drug label changes, such as new restrictions, 
contraindications or dose limitations. It is a quality process 
that could be implemented by clinical pharmacists in other 
primary care practices to enhance the safe prescribing of 
medication for women of childbearing age. 
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Table 1. Demographics (n=35) 
Variable n (%) 
Provider type 
   G1 
   G2 
   G3 
   Faculty physician 
   NP 
 
6 (17.1) 
8 (22.9) 
10 (28.6) 
10 (28.6) 
1 (2.9) 
Gender 
   Male 
   Female 
 
12 (34.3) 
23 (65.7) 
 
 
 
 
 
Table 2. Provider Agreement with Value and Change Statements 
Statement Strongly 
Disagree, 
n (%) 
Disagree, 
 n (%) 
Neither 
Disagree nor 
Agree, 
n (%) 
Agree, 
n (%) 
Strongly 
Agree, 
n (%) 
The monitoring of my prescribing of 
pregnancy category D/X medications in 
women of childbearing age is valuable 
(n=31) 
0  0 0 10 (32.3) 21 (67.7) 
The monitoring process used by the clinic 
is valuable (n=30) 
0 0 0 12 (40.0) 18 (60.0) 
As a result of the monitoring process, I 
plan to change how I approach prescribing 
pregnancy category D/X medications in 
women of childbearing age (n=31) 
0 1 (3.2) 4 (12.9) 19 (61.3) 7 (22.6) 
As a result of the monitoring process, I 
have changed how I approach prescribing 
pregnancy category D/X medications in 
women of childbearing age (n=31) 
0 1 (3.2) 10 (33.3) 12 (38.7) 8 (25.8) 
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Table 3. Frequency Provider Considered Pregnancy Status and Contraception Use 
How often did you think about the pregnancy status and 
contraception use of a woman of childbearing age when 
prescribing medication 
Before Monitoring Process 
(n=30), 
n (%) 
After Monitoring Process 
(n=31), 
n (%) 
Always 0 (0.0) 4 (12.9) 
Frequently 8 (26.7) 20 (64.5) 
Sometimes 17 (56.7) 6 (19.4) 
Rarely 4 (13.3) 1 (3.2) 
Never 1 (3.3) 0 (0.0) 
 
 
Table 4. Open-Ended Questions and Responses 
How has the monitoring of pregnancy category D and X medications in women of childbearing age changed your 
prescribing practices? 
• “Better counseling of women of child bearing age on importance of contraception when on certain 
medications.” 
• “Great reminder to keep this in mind with all young women.” 
• “I am mindful of my practice when prescribing medications to woman of childbearing age.” 
• “I am more likely to ask about contraception when managing chronic medical conditions in women of 
child bearing age.”   
• “I am more mindful of category of a medication when providing it to women of childbearing age.” 
• “I now think about a reliable birth control more.” 
• “I think that I am often cognizant when in clinic or precepting residents of a women's age and fertility 
status. This process has taught me that there are a few women that have slipped through the cracks, 
whether by my own prescriptions or by another physicians. This process served as another reinforcement 
of good medical practice.” 
• “It made me realize that many of my patient's of child-bearing age are on D/X medications- it made me 
aware of the volume of potential risks for many patients. I now think about warning women of the risks in 
pregnancy- which I did not before. Previously I had only thought about pregnancy risks really in women 
who were already pregnant or trying.” 
• “It triggered me to think about it before prescribing certain BP meds.” 
• “More cautious that they are on a reliable method.” 
What do you value about this monitoring process? 
• “Easy to use.” 
• “Getting the list of patients where it is not clear about their contraception status.  
• “Improved patient care.” 
• “It's a reminder system and allows me to review patients and contact them if I feel it is appropriate.”   
• “Keeping my patients safe.  Also, this process has made it easy for me to review my patients and make 
changes very quickly and efficiently.” 
• “Reminders are great.” 
• “The lists were created for us so it was easy to review the charts.” 
What suggestions for improvement do you have for the monitoring process used at the clinic? 
• “Have the medications in our faces, like on a small laminated card.”  
• “More frequent monitoring!” 
• “None.” 
• “Please keep monitoring, don't stop!” 
• “The patients on our list were ones that we don't see frequently.  I think this is why they were on the list 
because when I see them more often, I remember to ask about contraception.  It was very challenging to 
contact these patients.  I sent a letter to one, but am not sure if she got it as both numbers in the chart 
were not working.”   
 
